Table 1.
Characteristics of study cohorts
| Group |
Discovery cohort |
Validation cohort |
||
|---|---|---|---|---|
| Chemoresistant OS (n=6) | Control (n=6) | Chemoresistant OS (n=35) | Control (n=35) | |
| Age (years) | ||||
| Mean±SD |
9.6±4.2 |
9.6±4.2 |
9.9±4.9 |
10.1±5.2 |
| Range |
7–14 |
7–14 |
6–16 |
6–16 |
| Gender n (%) | ||||
| Male |
3 (50) |
3 (50) |
21 (60) |
23 (66) |
| Female |
3 (50) |
3 (50) |
14 (40) |
12 (34) |
| Tumor stage n (%) | ||||
| Stage IIA |
2 (33) |
2 (33) |
8 (23) |
7 (20) |
| Stage IIB |
2 (33) |
2 (33) |
13 (37) |
13 (37) |
| Stage III |
2 (33) |
2 (33) |
14 (40) |
15 (43) |
| Body mass index (kg/m2) |
17.5±4.0 |
18.2±4.1 |
17.7±3.8 |
18.3±4.0 |
| Tumor necrosis (%) | 94.1±2.8 | 70.8±9.2* | 93.5±3.6 | 73.6±12.2* |
Note: OS osteosarcoma. *p < 0.05 vs Chemoresistant OS.